CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Suzhou Zelgen Biopharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Suzhou Zelgen Biopharmaceuticals Co Ltd
No. 209, Chenfeng Road, Kunshan City
Phone: +86 51257011882p:+86 51257011882 SUZHOU, JNG  215300  China Ticker: 688266688266
Business Summary
Suzhou Zelgen Biopharmaceuticals Co Ltd is a China-based company primarily engaged in biopharmaceutical business. The Company focuses on the discovery, development and commercialization of innovative small molecule and biologic therapies, with a focus on oncology, autoimmune diseases and hemostasis/hematologic disorders. The Company has built a small molecule drug development platform, as well as bispecific/trispecific antibody and complex recombinant protein development platforms. The main products include donafenib tosylate tablets, gecacitinib hydrochloride tablets, recombinant human thrombin and human thyroid-stimulating hormone beta for injection. The Company operates in both the domestic market and overseas markets.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager ZelinSheng 66 2/27/2019 2/27/2019
Finance Director, Deputy General Manager GangHuang 55 2/27/2019 2/27/2019
Executive Vice President, Co-Chief Scientific Officer, Deputy General Manager, Director BinhuaLu 47 1/1/2025 2/27/2019
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,055 (As of 12/31/2025)
Outstanding Shares: 264,708,186 (As of 3/31/2026)
Shareholders: 9,369
Stock Exchange: SHA
Fax Number: +86 51257018306


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 12, 2026